High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
Call it a major breakthrough for diagnostic imaging
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Subscribe To Our Newsletter & Stay Updated
